<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00071461</url>
  </required_header>
  <id_info>
    <org_study_id>AC-052-320</org_study_id>
    <secondary_id>BUILD 1</secondary_id>
    <nct_id>NCT00071461</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>BUILD 1</acronym>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Idiopathic Pulmonary Fibrosis, Open Label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endothelin-1 (ET-1) is expressed in a variety of pulmonary pathological conditions including
      pulmonary vascular disease and pulmonary fibrosis.

      Bosentan (an oral dual ET-1 receptor antagonist) could delay the progression of idiopathic
      pulmonary fibrosis (IPF), a condition for which no established treatment is available.

      The present trial investigates a possible use of bosentan, which is currently approved for
      the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO class III and IV, to a
      new category of patients suffering from IPF.

      It was decided to offer Open Label treatment (bosentan) for patients willing to continue in
      the BUILD 1 study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 6-minute walk distance</measure>
    <time_frame>Baseline to End-of-Period 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death or treatment failure</measure>
    <time_frame>Up to End-of-Period 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial dose: 62.5 mg b.i.d. for 4 weeks.
Target dose: - body weight &gt; 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).
body weight &lt; 40 kg (90 lb): 62.5 mg b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Initial dose: 62.5 mg b.i.d. for 4 weeks.
Target dose: - body weight &gt; 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).
body weight &lt; 40 kg (90 lb): 62.5 mg b.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>Initial dose: 62.5 mg b.i.d. for 4 weeks.
Target dose: - body weight &gt; 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).
body weight &lt; 40 kg (90 lb): 62.5 mg b.i.d.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Tracleer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Initial dose: 62.5 mg b.i.d. for 4 weeks.
Target dose: - body weight &gt; 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).
body weight &lt; 40 kg (90 lb): 62.5 mg b.i.d.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients over 18 years of age.

               -  Women must be either postmenopausal (i.e., amenorrhea for at least 1 year), or
                  surgically or naturally sterile.

               -  Women of childbearing potential must have a negative pre-treatment pregnancy test
                  and use a reliable method of contraception during study treatment and for at
                  least 3 months after study treatment termination.

          2. IPF proven diagnosis &lt; 3 years documented according to ATS/ERS international
             multidisciplinary consensus, with or without surgical (thoracoscopic or open) chest
             lung biopsy

          3. Duration of illness ≥ 3 months.

          4. Six-minute walk test distance (limited by dyspnea) ≥ 150 meters and &lt; 500 meters

          5. Patients who have signed the informed consent form prior to initiation of any study
             procedure.

        Exclusion Criteria:

          1. Interstitial lung disease due to conditions other than IPF, including but not limited
             to radiation, sarcoidosis, hypersensitivity pneumonitis, bronchiolitis obliterans with
             organizing pneumonia, and cancer.

          2. History of clinically significant environmental exposure known to cause pulmonary
             fibrosis (drugs, asbestos, beryllium, radiation, domestic birds, etc.).

          3. Severe concomitant illness limiting life expectancy (&lt; 1 year).

          4. FVC ≥ 90% predicted.

          5. Severe restrictive lung disease: FVC &lt; 50% predicted or FVC &lt; 1.2 l, or DLco &lt; 30%
             predicted or residual volume ≥ 120% predicted.

          6. Severe obstructive lung disease: FEV1/FVC&lt; 0.65.

          7. Documented improvement of patient's condition within 12 months prior to randomization
             with or without IPF-specific therapy (e.g., corticosteroids, immunosuppressive,
             cytotoxic or antifibrotic drugs, TNFa blocker, interferon g).

          8. Recent pulmonary or upper respiratory track infection (within 4 weeks of
             randomization).

          9. PaO2 &lt; 55 mm Hg (sea level) or 50 mm Hg (altitude) at rest on room air.

         10. Echocardiographic evidence of severe pulmonary hypertension (PH): systolic pulmonary
             pressure ≥ 50 mm Hg or tricuspid regurgitation velocity ≥ 3.2 m/sec (unless severe PH
             is invalidated by a right heart catheterization). If the pulmonary pressure is not
             quantifiable, presence of significant right ventricular enlargement or hypertrophy or
             right ventricular dysfunction.

         11. Severe chronic heart failure, e.g., NYHA class III or IV and/or left ventricular
             ejection fraction &lt; 25%.

         12. Acute or chronic impairment (other than dyspnea) limiting the ability to comply with
             study requirements, e.g., the 6MWT or the PFTs.

             (e.g., angina pectoris, intermittent claudicating, chronic arthritis).

         13. Baseline values of liver transaminases, i.e., aspartate aminotransferases (AST) and/or
             alanine aminotransferases (ALT) &gt; 3 times the upper limit of normal ranges.

         14. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.

         15. Serum creatinine ≥ 2.5 mg/dl (221 mmol/l) or dialysis.

         16. Hemoglobin concentration &lt; 75% the lower limit of normal ranges.

         17. Systolic blood pressure &lt; 85 mm Hg.

         18. Pregnancy or breast-feeding.

         19. Current drug or alcohol dependence.

         20. Smoker (≥ 5 cigarettes per day) or former smoker (≥ 5 cigarettes per day) having
             stopped less than 6 months prior to randomization.

         21. Recently started (&lt; 8 weeks from Screening visit) or planned cardio-pulmonary
             rehabilitation program based on exercise.

         22. Treatment with oral corticosteroids (&gt; 15 mg/day prednisone or equivalent),
             immunosuppressive, cytotoxic or antifibrotic drugs such as TNF alpha blocker, or
             interferon gamma within 4 weeks of randomization.within 4 weeks of randomization.

         23. Treatment with glibenclamide (glyburide), cyclosporine A or tacrolimus within 1 weeks
             of randomization.

         24. Treatment with an endothelin receptor antagonist within 3 months of randomization.

         25. Treatment within 3 months of randomization or planned treatment with another
             investigational drug.

         26. Known hypersensitivity to bosentan or any of the excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham - Pulmonary Division</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA - Division of Pulmonary and Critical Care Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - Ambulatory Care Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics - Department of Internal Medicine</name>
      <address>
        <city>Iowa city</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System - Division of Pulmonary &amp; Critical Care Medicine</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Medical School - Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington - Division of Pulmonary &amp; Critical Care Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospitals &amp; Clinics - Section of Pulmonary and Critical Care Medicine</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia - St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosedale Medical Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4X 1W4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Notre-Dame Hospital - Clinique du Thorax</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne - Université de Paris</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Médecine Spécialisée Aigüe - CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abt. Pneumologie Medizinische Klinik Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Löwenstein gGmbH</name>
      <address>
        <city>Loewenstein</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik I Klinikum der Universität München</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Section of Respiratory Diseases - Policlinico Le Scotte - Siena University</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2003</study_first_submitted>
  <study_first_submitted_qc>October 23, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2003</study_first_posted>
  <disposition_first_submitted>February 11, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 11, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 15, 2010</disposition_first_posted>
  <last_update_submitted>February 22, 2012</last_update_submitted>
  <last_update_submitted_qc>February 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic pulmonary fibrosis</keyword>
  <keyword>Interstitial lung disease</keyword>
  <keyword>Bosentan</keyword>
  <keyword>BUILD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

